公开(公告)号：US09649375B2

公开(公告)日：2017-05-16

申请号：US13828988

申请日：2013-03-14

申请人： The Administrators of the Tulane Educational Fund

发明人： Robert Francis Garry ,  Russell B. Wilson

IPC分类号： A61K39/395 ,  A61K39/12 ,  A61K39/00 ,  C07K14/005 ,  C07K16/10 ,  C07K17/02

CPC分类号： A61K39/3955 ,  A61K39/12 ,  A61K2039/6081 ,  C07K14/005 ,  C07K16/1018 ,  C07K17/02 ,  C07K2317/33 ,  C12N2760/16122 ,  C12N2760/16134

摘要： Immunogenic influenza hemagglutinin-derived peptide conjugates described herein induce a specific therapeutic antibody response against influenza virus. The immunogenic peptide conjugates comprise a segment from the fusion initiation region (FIR) domain of an influenza hemagglutinin protein conjugated to an immunogenic carrier protein, such as keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA), an influenza hemagglutinin (HA) protein (i.e., full length HA), and the like. The immunogenic peptide conjugates described herein can be utilized to treat or prevent influenza infection and to prepare influenza-specific therapeutic antibodies that interfere with influenza virus-host cell membrane fusion. The peptide conjugates can be formulated in pharmaceutical compositions useful for broad spectrum treatment or prevention of influenza infections.

公开(公告)号：US20170049849A9

公开(公告)日：2017-02-23

申请号：US14505101

申请日：2014-10-02

申请人： THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND ,  MCGILL UNIVERSITY

发明人： Cyril Y. BOWERS ,  David H. COY ,  Simon J. HOCART ,  Gloria S. TANNENBAUM

IPC分类号： A61K38/10 ,  A61K38/08

CPC分类号： A61K38/10 ,  A61K31/167 ,  A61K31/404 ,  A61K31/44 ,  A61K31/4418 ,  A61K31/495 ,  A61K38/08 ,  A61K38/22 ,  A61K45/06 ,  C07K7/06 ,  C07K7/08 ,  Y02P20/55 ,  A61K2300/00

摘要： The invention provides methods for treatment, prevention or management of obesity, obesity related disorders, diabetes mellitus, and metabolic syndrome in a subject by administering a ghrelin O-acyltransferase (GOAT) inhibitor and/or a ghrelin receptor antagonist to the subject. The invention also provides ghrelin receptor antagonists of formula (VII): A11-A12-A13-Gly-Ser-A14-Phe-Leu-A15-A16-A17-A18, wherein each of A11, A12, and A13 is independently absent, an amino acid, or an amino protecting group; each of A15, A16, A17, and A18 is independently absent or an amino acid; and A14 is a serine conjugated with a —C(O)C1-C20alky or a diaminopropionic acid conjugated with a —C(O)C1-C20alkyl group, provided that at least one of A11, A12, or A13 is present.

摘要翻译： 本发明通过向受试者施用生长素释放肽O-酰基转移酶（GOAT）抑制剂和/或生长素释放肽受体拮抗剂来提供治疗，预防或控制受试者中肥胖症，肥胖相关病症，糖尿病和代谢综合征的方法。 本发明还提供式（VII）的生长素释放肽受体拮抗剂：A11-A12-A13-Gly-Ser-A14-Phe-Leu-A15-A16-A17-A18，其中A11，A12和A13各自独立地不存在， 氨基酸或氨基保护基; A15，A16，A17和A18各自独立地不存在或氨基酸; 并且A14是与-C（O）C1-C20烷基或与-C（O）C1-C20烷基共轭的二氨基丙酸缀合的丝氨酸，条件是存在A11，A12或A13中的至少一种。

公开(公告)号：US09568462B2

公开(公告)日：2017-02-14

申请号：US14851281

申请日：2015-09-11

申请人： The Administrators of the Tulane Educational Fund

发明人： Wayne F. Reed

IPC分类号： C08F2/00 ,  A61L2/28 ,  G01N33/00 ,  C40B30/10 ,  G01N33/44 ,  B01J19/00 ,  G01N21/25 ,  G01N21/53 ,  G01N21/82 ,  G01N1/32 ,  G01N21/05 ,  G01N21/64 ,  G01N21/47 ,  G01N21/84

CPC分类号： G01N33/442 ,  B01J19/0006 ,  B01J19/0033 ,  B01J2219/00063 ,  B01J2219/00177 ,  B01J2219/00186 ,  B01J2219/002 ,  C08F2/001 ,  G01N1/32 ,  G01N21/05 ,  G01N21/253 ,  G01N21/47 ,  G01N21/49 ,  G01N21/53 ,  G01N21/64 ,  G01N21/82 ,  G01N33/44 ,  G01N2021/054 ,  G01N2021/4742 ,  G01N2021/4769 ,  G01N2021/8411 ,  Y02P20/582

摘要： A method of monitoring the evolution of polymer and/or colloid stimuli responsiveness during synthesis of polymers and/or colloids, including postpolymerization modifications on natural and synthetic polymers, includes providing a reactor in which the polymers and/or colloids are synthesized; and providing a means of monitoring the stimuli responsiveness of the polymers and/or colloids during said synthesis. Preferably, the method also includes monitoring the evolution of the characteristics of the polymers and/or colloids during said synthesis. Preferably, evolution of polymer and/or colloid stimuli responsiveness is correlated to the evolution of the properties of the polymers and/or colloids themselves. Also, preferably the conditions of the fluid in the reactor in which the synthesis occurs is determined. The determination can be by detection, choice of materials and temperature conditions, for example, and combinations thereof. The method and instrumentation disclosed can lead to optimization and control of processes and synthetic and modification strategies leading to polymers and colloids with desired stimuli responsiveness.

摘要翻译： 监测合成聚合物和/或胶体期间聚合物和/或胶体刺激响应性的方法，包括天然和合成聚合物的后聚合改性，包括提供其中合成聚合物和/或胶体的反应器; 并且提供在所述合成期间监测聚合物和/或胶体的刺激响应性的手段。 优选地，该方法还包括在所述合成期间监测聚合物和/或胶体的特性的演变。 优选地，聚合物和/或胶体刺激反应性的演变与聚合物和/或胶体本身的性质的演变相关。 此外，优选确定发生合成的反应器中的流体的条件。 该测定可以通过检测，材料的选择和温度条件，例如及其组合。 所公开的方法和仪器可以导致优化和控制过程和合成和修饰策略，导致具有期望的刺激反应性的聚合物和胶体。

公开(公告)号：US20150209487A1

公开(公告)日：2015-07-30

申请号：US14633282

申请日：2015-02-27

申请人： The Administrators of the Tulane Educational

发明人： Diane A. BLAKE ,  Vijay T. John ,  Ramesh Ayyala ,  Krzysztof Reiss

IPC分类号： A61L31/16 ,  A61L31/10 ,  B29D7/01 ,  B29C39/08 ,  B29C39/12 ,  A61L31/14 ,  B29C39/00

CPC分类号： A61L31/16 ,  A61F9/00781 ,  A61K9/7007 ,  A61K31/216 ,  A61K31/407 ,  A61K31/513 ,  A61K47/34 ,  A61L31/10 ,  A61L31/146 ,  A61L31/148 ,  A61L2300/414 ,  A61L2300/434 ,  A61L2300/45 ,  A61L2420/06 ,  A61L2420/08 ,  A61M37/00 ,  B29C39/003 ,  B29C39/08 ,  B29C39/123 ,  B29D7/01 ,  B29K2033/00 ,  B29K2995/0056 ,  B29K2995/006 ,  C08L71/02 ,  C08L67/04 ,  A61K2300/00

摘要： The disclosure provides drug delivery devices and methods of making and using the drug delivery devices. The devices include single and multi-layer polymer films made by a breath figure technique having therapeutic agents associated therewith. For example, the devices may be a dual layer polymer film wherein the first layer includes a therapeutic agent incorporated into it by spin coating the first agent with a polymer solution and the second agent is incorporated into the second layer by loading the agent into pores of the second layer after it is spin coated onto the first layer. In some cases one layer provides a burst release and the second layer provides a slow release drug delivery profile. The devices may take on the form of a surgical mesh with a slow release therapeutic drug.

摘要翻译： 本公开提供了药物递送装置和制备和使用药物递送装置的方法。 这些装置包括通过具有与其相关联的治疗剂的呼吸图技术制备的单层和多层聚合物膜。 例如，所述装置可以是双层聚合物膜，其中第一层包括通过用聚合物溶液旋涂第一试剂而掺入其中的治疗剂，并且通过将试剂加载到第二层的孔中 第二层被旋涂在第一层上。 在一些情况下，一层提供爆发释放，第二层提供缓释药物递送分布。 装置可以采取具有缓释治疗药物的外科手术网的形式。

公开(公告)号：US20150153367A1

公开(公告)日：2015-06-04

申请号：US14403365

申请日：2013-05-22

申请人： New Health Sciences, Inc. ,  The Administrators of the Tulane Educational Fund

发明人： Tatsuro Yoshida ,  Sergey S. Shevkoplyas ,  Jennie M. Burns

IPC分类号： G01N33/80 ,  B01L3/00

CPC分类号： G01N33/80 ,  B01L3/5027 ,  B01L3/502715 ,  B01L2300/0838 ,  B01L2300/0861 ,  B01L2300/0867

摘要： Artificial microvascular network (AMVN) devices are provided and related methods of making and methods of using such devices are provided. The present disclosure generally relates to an AMVN device comprising a substrate including a capillary network configured so as to simulate those actually encountered in the circulation of various humans and animal model systems. In certain aspects, the AMVN devices may be used, e.g., to investigate the effect of storing RBCs under aerobic and anaerobic conditions. However, the use of such AMVN devices is not so limited.

摘要翻译： 提供人造微血管网络（AMVN）装置，并提供相关的制造方法和使用这些装置的方法。 本公开总体上涉及一种AMVN装置，其包括基底，该基底包括毛细管网络，该毛细管网被配置为模拟在各种人类和动物模型系统的循环中实际遇到的那些毛细管网络。 在某些方面，可以使用AMVN装置，例如研究在需氧和厌氧条件下储存RBC的效果。 然而，使用这样的AMVN设备并不限于此。

公开(公告)号：US20150112244A1

公开(公告)日：2015-04-23

申请号：US14583708

申请日：2014-12-28

申请人： The Administrators of the Tulane Educational Fund

发明人： Elaine Horn-Ranney ,  Parastoo Khoshakhlagh ,  Michael Moore ,  Jesse Ranney

IPC分类号： A61L27/14 ,  A61K38/38 ,  A61L27/54 ,  A61L27/52 ,  A61L27/56 ,  A61N5/06 ,  A61L27/20

CPC分类号： A61L27/14 ,  A61K38/385 ,  A61L27/20 ,  A61L27/52 ,  A61L27/54 ,  A61L27/56 ,  A61L2430/14 ,  A61N5/062 ,  C08L5/08

摘要： Otologic materials and methods are provided. For example, a cell-adhesive, biodegradable hydrogel scaffold loaded with time-released drugs for repairing chronic tympanic membrane perforations is disclosed, methods of making same and administering same are provided. This hydrogel may promote vascular in-growth and epithelial cell growth of the tympanic membrane with the purpose of closing the perforation and providing a barrier between the external and middle ear. The hydrogel is initially a liquid polymer that only gels upon exposure to specific conditions, such as exposure to light. This scaffold may simultaneously induce repair of the tympanic membrane while preventing or alleviating middle ear infection, thus filling a void in current tympanic membrane perforation therapies.

摘要翻译： 提供耳科材料和方法。 例如，公开了装载用于修复慢性鼓膜穿孔的时间释放药物的细胞粘附的可生物降解的水凝胶支架，提供制备方法和施用方法。 该水凝胶可以促进鼓膜的血管生长和上皮细胞生长，目的是关闭穿孔并在外耳和中耳之间提供屏障。 水凝胶最初是液体聚合物，其仅在暴露于特定条件（例如暴露于光）时凝胶化。 这种支架可以同时诱导鼓膜修复，同时预防或减轻中耳感染，从而填补目前鼓膜穿孔治疗中的空隙。

公开(公告)号：US08987198B2

公开(公告)日：2015-03-24

申请号：US12976209

申请日：2010-12-22

申请人： Matthew E. Burow ,  Stephen M. Boue ,  Thomas T. Y. Wang ,  Deepak Bhatnagar ,  Charles E. Wood ,  Mark L. Helman

发明人： Matthew E. Burow ,  Stephen M. Boue ,  Thomas T. Y. Wang ,  Deepak Bhatnagar ,  Charles E. Wood ,  Mark L. Helman

IPC分类号： A61K38/28 ,  A61K38/00 ,  A61K31/352 ,  A61K31/52

CPC分类号： A61K31/352 ,  A61K31/52 ,  A61K38/28 ,  A61K2300/00

摘要： Disclosed are methods of modulating the expression of genes linked to adipocytokine signaling, carbohydrate metabolism, fatty acid metabolism, arachidonic acid metabolism, PPAR signaling, insulin signaling, lipid metabolism, extracellular matrix (ECM)-receptor interaction, or combinations thereof, methods of treating hyperlipidemia, obesity, excessive cholesterol, cardiovascular disease, liver disease, diabetes, or combinations thereof, and methods of stimulating glucose uptake in an animal in need thereof, comprising administering a composition comprising at least one isolated glyceollin to said animal.

摘要翻译： 公开了调节与脂肪细胞因子信号转导，碳水化合物代谢，脂肪酸代谢，花生四烯酸代谢，PPAR信号传导，胰岛素信号转导，脂质代谢，细胞外基质（ECM） - 受体相互作用或其组合相关基因表达的方法，治疗方法 高脂血症，肥胖症，过度胆固醇，心血管疾病，肝病，糖尿病或其组合，以及刺激有需要的动物中的葡萄糖摄取的方法，包括向所述动物施用包含至少一种分离的葡萄糖苷的组合物。

公开(公告)号：US08968576B2

公开(公告)日：2015-03-03

申请号：US11292328

申请日：2005-11-30

申请人： Jennifer E. Holland ,  Robert S. Reimers

发明人： Jennifer E. Holland ,  Robert S. Reimers

IPC分类号： C02F1/32 ,  C02F1/72 ,  A61M15/02 ,  B01D53/86 ,  B01D53/90 ,  C02F1/30 ,  C02F1/36 ,  C02F1/78 ,  C02F101/22

CPC分类号： C02F1/72 ,  A61M15/02 ,  A61M2205/3317 ,  B01D53/8687 ,  B01D53/90 ,  B01D2251/102 ,  B01D2251/104 ,  B01D2255/207 ,  B01D2255/20707 ,  B01D2255/20753 ,  B01D2255/20776 ,  B01D2255/20792 ,  B01D2255/802 ,  B01D2257/708 ,  B01D2258/06 ,  B01D2259/4508 ,  B01D2259/804 ,  B01D2259/806 ,  B01D2259/81 ,  B01D2259/812 ,  B01D2259/816 ,  C02F1/30 ,  C02F1/302 ,  C02F1/307 ,  C02F1/32 ,  C02F1/36 ,  C02F1/722 ,  C02F1/725 ,  C02F1/78 ,  C02F2101/22 ,  C02F2303/04 ,  C02F2305/023 ,  C02F2305/08 ,  C02F2305/10 ,  Y02A50/2327

摘要： A method of treating contaminated air, gas and surfaces is accomplished through the nebulization of gas and/or liquid oxidants through a field of electromagnetic radiation or sonic waves. The contaminated gas and/or liquid streams are blended with gaseous and/or liquid oxidants by the nebulizer and directly injected in the energy field. Free radicals produced from oxidants in the presence of the energy field instantaneously oxidize a large effective surface area of the contaminated media. Surfaces are treated more efficiently with the energy field situated directly above and parallel to but not on the surface; a high-frequency energy field may be used to create a large concentration of free radicals without damaging the surface in a collimated beam of the field situated parallel to the surface. A catalyst may be employed at the tip (i.e. discharge orifices of gas and/or liquid) of the nebulizer or blended into the nebulized cloud to increase the formation of free radicals. The method may also be used to carry out a reduction instead of an oxidation reaction.

摘要翻译： 处理受污染的空气，气体和表面的方法是通过气体和/或液体氧化剂通过电磁辐射或声波的场雾化来实现的。 污染的气体和/或液体流通过喷雾器与气体和/或液体氧化剂混合并直接注入能量场。 在能量场存在下由氧化剂产生的自由基瞬间氧化受污染介质的大的有效表面积。 表面被更有效地处理，能量场直接位于和平行但不在表面上; 可以使用高频能量场来产生大的浓度的自由基，而不损害平行于表面的场的准直光束中的表面。 可以在喷雾器的尖端（即，气体和/或液体的排出孔）处使用催化剂或者混合到雾化云中以增加自由基的形成。 该方法也可用于进行还原而不是氧化反应。

公开(公告)号：US08916517B2

公开(公告)日：2014-12-23

申请号：US13505370

申请日：2010-11-02

申请人： David H. Coy ,  Jerome L. Maderdrut ,  Min Li

发明人： David H. Coy ,  Jerome L. Maderdrut ,  Min Li

IPC分类号： A61K38/17 ,  C07K14/435 ,  A61P11/00 ,  A61P13/12 ,  A61P1/00 ,  A61P27/02 ,  A61P37/06 ,  A61P9/00 ,  A61P9/12 ,  A61P35/00 ,  A61P3/04 ,  A61P3/10 ,  A61K45/06 ,  C07K14/575 ,  A61K33/24 ,  A61K38/00

CPC分类号： C07K14/57563 ,  A61K33/24 ,  A61K38/00 ,  A61K38/2278 ,  A61K45/06 ,  A61K47/64 ,  A61K51/088 ,  A61L31/08 ,  A61L31/16 ,  A61L2300/252 ,  A61L2300/40 ,  A61L2420/00 ,  C07K2319/50 ,  A61K2300/00

摘要： This invention relates to novel analogs of pituitary adenylate cyclase-activating polypeptide (PACAP), which are agonists for the PACAP/vasoactive intestinal peptide (VIP) receptors: PAC1, VPAC1 and VPAC2 receptors. These PACAP analogs can be used as prophylactic/therapeutic agents for a wide range of medical disorders, including (but not limited to) cancer and autoimmune disease. These PACAP analogs can be coupled to suitable radionuclides and used in the localization, diagnosis and treatment of disseminated cancers and metastatic tumors, or coupled to small molecule therapeutics and used as vectors for targeted drug delivery. This invention also provides pharmaceutical compositions of one or more PACAP-like compounds of the invention either alone or in combination with one or more other prophylactic/therapeutic agents.

摘要翻译： 本发明涉及垂体腺苷酸环化酶活化多肽（PACAP）的新型类似物，其是PACAP /血管活性肠肽（VIP）受体的激动剂：PAC1，VPAC1和VPAC2受体。 这些PACAP类似物可以用作广泛的医学疾病的预防/治疗剂，包括（但不限于）癌症和自身免疫性疾病。 这些PACAP类似物可以耦合到合适的放射性核素，并用于弥散性癌症和转移性肿瘤的定位，诊断和治疗，或与小分子治疗剂偶联，并用作靶向药物递送的载体。 本发明还提供单独一种或与一种或多种其它预防/治疗剂组合的本发明的一种或多种PACAP样化合物的药物组合物。

公开(公告)号：US08883721B2

公开(公告)日：2014-11-11

申请号：US13320408

申请日：2010-05-12

申请人： Cyril Y. Bowers ,  David H. Coy ,  Simon J. Hocart ,  Gloria S. Tannenbaum

发明人： Cyril Y. Bowers ,  David H. Coy ,  Simon J. Hocart ,  Gloria S. Tannenbaum

IPC分类号： A61K38/08 ,  A61K38/10 ,  C07K7/06 ,  C07K7/08 ,  A61K31/00 ,  A61K45/06 ,  A61K31/404 ,  A61K38/16 ,  A61K38/25

CPC分类号： A61K38/08 ,  A61K31/00 ,  A61K31/404 ,  A61K38/10 ,  A61K38/16 ,  A61K38/25 ,  A61K45/06 ,  A61K2300/00

摘要： The invention provides methods for treatment, prevention or management of obesity, obesity related disorders, diabetes mellitus, and metabolic syndrome in a subject by administering a ghrelin O-acyltransferase (GOAT) inhibitor and/or a ghrelin receptor antagonist to the subject. The invention also provides ghrelin receptor antagonists of formula (VII): A11-A12-A13-Gly-Ser-A14-Phe-Leu-A15-A16-A17-A18 (SEQ ID NO: 93), wherein each of A11, A12, and A13 is independently absent, an amino acid, or an amino protecting group; each of A15, A16, A17, and A18 is independently absent or an amino acid; and A14 is a serine conjugated with a —(O)C1-C20alky or a diaminopropionic acid conjugated with a —C(O)C1-C20alkyl group, provided that at least one of A11, A12, or A13 is present.

摘要翻译： 本发明通过向受试者施用生长素释放肽O-酰基转移酶（GOAT）抑制剂和/或生长素释放肽受体拮抗剂来提供治疗，预防或控制受试者中肥胖症，肥胖相关病症，糖尿病和代谢综合征的方法。 本发明还提供式（VII）的生长素释放肽受体拮抗剂：A11-A12-A13-Gly-Ser-A14-Phe-Leu-A15-A16-A17-A18（SEQ ID NO：93），其中A11，A12 ，并且A13独立地不存在，氨基酸或氨基保护基; A15，A16，A17和A18各自独立地不存在或氨基酸; 并且A14是与-C（O）C1-C20烷基共轭的 - （O）C1-C20烷基或二氨基丙酸缀合的丝氨酸，条件是存在A11，A12或A13中的至少一种。